X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Biosimilar insulin glargine is the most significant opportunity in the company's current pipeline. Recent estimated U.S. sales of long acting insulin glargine (Glaricon) are approximately $10 billion annually, according to IQVIA, although manufacturer reported sales are less.
Lead Product(s): Insulin Glargine
Therapeutic Area: Endocrinology Product Name: Glaricon
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Lannett Company, Inc.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2022
Details:
The biosimilar insulin aspart is currently in development and Lannett will help manage the remaining clinical and regulatory steps specific for a U.S. Food and Drug Administration (FDA) approval to market the product.
Lead Product(s): Insulin aspart
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: Lannett
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
